Sandoz has announced that it has entered into a partnership with Taiwan-based biotechnology manufacturing and development company EirGenix, Inc, for a proposed trastuzumab biosimilar referencing Herceptin.
Sandoz has announced that it has entered into a partnership with Taiwan-based biotechnology manufacturing and development company EirGenix, Inc, for a proposed trastuzumab biosimilar referencing Herceptin.
Under the terms of the deal, EirGenix will develop and manufacture the biosimilar, while Sandoz will commercialize the product upon approval in all markets other than China and Taiwan. EirGenix will receive an upfront payment, milestone payments, and a share of profits from the biosimilar.
Sandoz indicated in a statement that this collaboration will allow the company to use its in-house resources to perpetuate its internal pipeline while further expanding its oncology portfolio and developing its hospital presence.
“Every year, approximately 300,000 people worldwide are diagnosed with HER2-positive breast cancer, which tends to spread more quickly than HER2-negative tumors, making swift treatment important. While targeted therapy is available, high out-of-pocket costs lead to limited treatment in the [United States,] and reimbursement issues have resulted in varying uptake in Europe,” said Stefan Hendriks, global head of biopharmaceuticals for Sandoz, in a statement. “Introducing biosimilars can help create earlier and expanded access to this important medicine, which is why I am so excited about the potential for this collaboration.”
The proposed biosimilar, EG12014, is currently in phase 3 clinical development, and EirGenix reports that the phase 3 trial in patients with breast cancer, begun in October 2018, will enroll a total of 800 patients. Patients will receive epirubicin and cyclophosphamide followed by either EG12014 or its reference plus paclitaxel. All patients will be scheduled for surgery 3 to 6 weeks after completion of neoadjuvant chemotherapy. The primary end point analysis is expected to be completed in the second half of 2020.
In May 2017, the company announced that the proposed biosimilar had demonstrated bioequivalence in a phase 1 clinical trial. The study was a double-blind, randomized, parallel group, 3-arm study in 84 healthy male volunteers. The study investigated the pharmacokinetic (PK) similarity between EG12014 and EU- and US-licensed reference Herceptin. According to the company, the study met its primary PK end point.
EirGenix also reports that it is developing a pertuzumab biosimilar referencing Perjeta, a bevacizumab biosimilar referencing Avastin, and an undisclosed biosimilar—all of which are in the preclinical phase—as well as novel drug agents.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.